<DOC>
	<DOC>NCT03004209</DOC>
	<brief_summary>This study evaluates the efficacy of erythropoietin in refractory autoimmune encephalitis. Ten patients will receive 100 IU/kg of erythropoietin 3 times a week for 12 weeks.</brief_summary>
	<brief_title>Effect of Erythropoietin in Refractory Autoimmune Encephalitis Patients</brief_title>
	<detailed_description>Erythropoietin can improve the refractory autoimmune encephalitis. Erythropoietin has tissue-protective effect via activation of Janus kinase (JAK)-2, signal transducer and activator of transcription (STAT)-5 pathway and NF-kappa B pathway. The activation of JAK-2 and STAT-5 promote hemoglobin synthesis and facilitate cell cycle progression. Also, NF-kappa B pathway inhibition regulates pro-inflammatory cytokine production. We expect that erythropoietin may lead to improve the symptoms and outcome of autoimmune encephalitis.</detailed_description>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Hashimoto Disease</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Clinically diagnosed autoimmune encephalitis Ineffective 1st line treatment (e.g. steroid IV, IVIg) and 2nd line treatment (e.g. Rituximab or cyclophosphamide) Hemoglobin &gt; 12g/dL Hematochrit &gt;36% Thrombocytosis &gt; 750K AST or ALT &gt; 120 HIV (+) Allergic reaction upon erythropoietin Uncontrolled hypertension mRS before the autoimmune encephalitis &gt; 3 Breast feeding or pregnancy History of ischemic stroke or pulmonary thrombosis Refuse to be enrolled</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Erythropoietin</keyword>
	<keyword>Autoimmune encephalitis</keyword>
</DOC>